Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Average PT from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have earned a consensus recommendation of "Buy" from the five ratings firms that are covering the firm, MarketBeat reports. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $6.00.

A number of research analysts recently issued reports on CNTX shares. D. Boral Capital reiterated a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a research note on Thursday, May 8th. HC Wainwright reiterated a "buy" rating and set a $5.00 target price on shares of Context Therapeutics in a research note on Friday, March 21st. Finally, William Blair restated an "outperform" rating on shares of Context Therapeutics in a research note on Tuesday, April 29th.

Context Therapeutics Stock Down 5.1%

CNTX stock traded down $0.04 during midday trading on Tuesday, hitting $0.71. The company's stock had a trading volume of 102,223 shares, compared to its average volume of 290,639. The firm has a 50-day simple moving average of $0.78 and a 200-day simple moving average of $1.08. The firm has a market capitalization of $63.85 million, a P/E ratio of -0.78 and a beta of 2.11. Context Therapeutics has a 52-week low of $0.55 and a 52-week high of $2.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). On average, sell-side analysts expect that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CNTX. Jane Street Group LLC acquired a new position in Context Therapeutics in the fourth quarter valued at $29,000. Citadel Advisors LLC purchased a new position in Context Therapeutics during the 4th quarter worth approximately $31,000. Shay Capital LLC purchased a new position in Context Therapeutics during the 4th quarter worth approximately $52,000. Clear Harbor Asset Management LLC increased its position in Context Therapeutics by 60.6% during the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock worth $61,000 after buying an additional 21,804 shares during the period. Finally, Landscape Capital Management L.L.C. purchased a new stake in Context Therapeutics in the fourth quarter valued at approximately $94,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.